Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Bavarian Nordic

215.60 DKK-1.73 %4.9, 16.59
Less than 1K followers

BAVA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.73 %
+19.91 %
+20.18 %
+16.54 %
+12.97 %
-8.80 %
+39.41 %
-39.44 %
+51.16 %

Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Read more
Market cap
17.08B DKK
Turnover
37.39M DKK
Revenue
6.24B
EBIT %
28.89 %
P/E
12.25
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
13.11
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release04.09.2026, 18.00

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
Regulatory press release04.09.2026, 18.00

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer

Bavarian Nordic
Regulatory press release04.09.2026, 08.20

Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner

Bavarian Nordic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release04.09.2026, 08.20

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Bavarian Nordic
Regulatory press release01.09.2026, 07.30

Bavarian Nordic lancerer første del af nyt aktietilbagekøbsprogram

Bavarian Nordic
Regulatory press release01.09.2026, 07.30

Bavarian Nordic Launches First Tranche of New Share Buy-Back Program

Bavarian Nordic
Regulatory press release25.08.2026, 21.00

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer

Bavarian Nordic
Regulatory press release25.08.2026, 21.00

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Bavarian Nordic
HCA Morgenbørs 24/08 - WindowMaster CEO-interview og negativ åbning i Europa
Video24.08.2026, 09.31 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 24/08 - WindowMaster CEO-interview og negativ åbning i Europa

Udsigt til negativ åbning i Europa efter kursfald i Asien her til morgen. Ingen større danske regnskaber i dag, men en lang række kursmålsændringer fra analytikerkorpset. Gæst i studiet her til morgen er CEO Erik Boyter fra WindowMaster.

Novo NordiskNovonesisChemoMeteccBrainBavarian NordicGubraWindowMaster International
HCA Morgenbørs 21/08 - BioPorto CFO-interview og svag positiv åbning
Video21.08.2026, 09.32 by
Michael Friis, Jacob Frehr

HCA Morgenbørs 21/08 - BioPorto CFO-interview og svag positiv åbning

Udsigt til en flad til svag positiv åbning i Europa. Scott Bessent redningsplan holdt ikke længe Fokus på regnskabsaktuelle Better Collective, Bavarian. Gæst i studiet her til morgen er BioPorto CFO Klaus Juhl Wulff.

BioPortoBetter CollectiveBavarian NordicGN Store NordSP GroupGubraNorth MediaNovonesisFLSmidth & Co.
Regulatory press release21.08.2026, 07.51

Bavarian Nordic Reports Strong First Half 2026 Results

Bavarian Nordic
Regulatory press release21.08.2026, 07.51

Bavarian Nordic leverer et stærkt regnskab for første halvår 2026

Bavarian Nordic
Regulatory press release21.08.2026, 07.48

Bavarian Nordic lancerer nyt aktietilbagekøbsprogram på op til DKK 750 mio.

Bavarian Nordic
Regulatory press release21.08.2026, 07.48

Bavarian Nordic to Launch New Share Buy-back Program of up to DKK 750 Million

Bavarian Nordic
Regulatory press release21.08.2026, 07.43

Bavarian Nordic opjusterer sine økonomiske forventninger til 2026

Bavarian Nordic
Regulatory press release21.08.2026, 07.43

Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance

Bavarian Nordic
Press release07.08.2026, 08.00

Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years

Bavarian Nordic
Press release07.08.2026, 08.00

Bavarian Nordic modtager Europa-Kommissionens godkendelse af mpox/koppevaccine til børn i alderen 2 til under 12 år

Bavarian Nordic
Press release13.07.2026, 15.00

Bavarian Nordics chikungunyavaccine indsendt til myndighedsgodkendelse i Brasilien

Bavarian Nordic
Press release13.07.2026, 15.00

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

Bavarian Nordic